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Abstract
Background: Asexual stage antibody responses following initial Plasmodium falciparum infections
in previously healthy adults may inform vaccine development, yet these have not been as intensively
studied as they have in populations from malaria-endemic areas.
Methods: Serum samples were collected over a six-month period from twenty travellers having
returned with falciparum malaria. Fourteen of these were malaria-naïve and six had a past history
of one to two episodes of malaria. Antibodies to seven asexual stage P. falciparum antigens were
measured by ELISA. Invasion inhibitory antibody responses to the 19kDa fragment of merozoite
surface protein 1 (MSP119) were determined.
Results: Short-lived antibody responses were found in the majority of the subjects. While MSP119
antibodies were most common, MSP1 block 2 antibodies were significantly less frequent and
recognized conserved domains. Antibodies to MSP2 cross-reacted to the dimorphic allelic families
and anti-MSP2 isotypes were not IgG3 skewed as shown previously. MSP119 invasion inhibiting
antibodies were present in 9/20 patients. A past history of malaria did not influence the frequency
of these short-lived, functional antibodies (p = 0.2, 2-tailed Fisher's exact test).
Conclusion: Adults infected with P. falciparum for the first time, develop relatively short-lived
immune responses that, in the case of MSP119, are functional. Antibodies to the polymorphic
antigens studied were particularly directed to allelic family specific, non-repetitive and conserved
determinants and were not IgG subclass skewed. These responses are substantially different to
those found in malaria immune individuals.
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Background
Understanding the native immune response to Plasmo-
dium falciparum infection is an important prerequisite for
successful vaccine development against this high priority
global disease. Many population studies performed in
areas of malaria transmission have correlated the presence
of antibodies to P. falciparum proteins with protection
from disease. In general, the non-sterilizing immunity to
malaria seen in adults living in areas hyperendemic for
malaria is acquired after numerous infections. Little, how-
ever, is known about antibody responses in previously
healthy adults after single infections with P. falciparum,
such as non-immune travellers.
Based on current information, a number of proteins are
being advanced as potentially useful components of a
subunit malaria vaccine. For example, MSP119, the car-
boxyl-terminal domain of merozoite surface protein-1
(MSP1) is highly conserved [1], serves a critical function
in erythrocyte invasion [2] and has been widely shown to
confer protective immunity in various models of malaria
infection [3]. The repetitive, block 2 region of MSP1 has
been identified as a major immune target by studies that
infer immune selection acting upon it and there is a strong
association between antibodies to this region and protec-
tion [4]. Other proteins, such as MSP2, have been shown
in recent field studies of a combination vaccine to induce
protective immune responses against homologous strains
of malaria [5]. The problem of antigenic diversity can be
extreme for some malaria proteins, such as MSP2 and api-
cal membrane antigen-1, and, accordingly, there has been
interest in relatively invariant proteins, such as MSP4 [6]
and MSP5 [7] that show good degrees of protection
against heterologous challenge in model systems of
malaria infection [8]. Other conserved proteins, such as
MSP6, MSP7 [9] and rhoptry associated membrane anti-
gen (RAMA) [10] induce strong responses during infec-
tion and an association has been shown between
antibody response and clinical immunity [10,11].
This study has assessed the immune responses in non-
immune adults mostly presenting with their first episode
of P. falciparum infection and characterized the pattern of
acquisition of antibodies to seven asexual stage proteins.
By systematically collecting a series of samples from these
individuals the timing, level and decline of these antibod-
ies has been characterized and a comparison of the immu-
nogenicity of various antigens been made. Antibody
responses to overlapping, dimorphic family specific
epitopes of MSP1 block 2 and dimorphic family specific
repetitive and non-repetitive regions of MSP2 were ana-
lysed to determine the specificity of responses to these tar-
gets. Immunoglobulin isotyping was performed for
antibodies to MSP119, MSP2, MSP4 and MSP7B, where
previous data have indicated isotype bias to assess
whether these patterns were present. Finally, the function-
ality of antibodies formed against MSP119 in a growth
inhibition assay has been measured.
Methods
Blood samples
Full blood and serum samples were collected with written
informed consent from twenty patients presenting to the
Royal Brisbane and Princess Alexandra Hospitals with fal-
ciparum malaria. The Human Research Ethics Commit-
tees of the Royal Brisbane and Princess Alexandra
Hospitals granted approval for the study. Parasitized
erythrocytes were stored in 8M GuHC1. Serum samples
were collected at around the time of diagnosis of P. falci-
parum infection then again at approximately one month
and six months after infection. Negative controls con-
sisted of 30 samples taken with informed consent from
Australian blood donors with no history of exposure to
malaria. Positive control sera consisted of samples taken
with informed consent from 20 hyperimmune, Papua
New Guinean (PNG) adults. The serum samples were
stored at -70°C.
MSP1 block 2 and MSP2 genotyping
A strategy was instituted to detect multiple infections to
aid the interpretation of antibody responses to MSP1
block 2 and MSP2 dimorphic family alleles. MSP1 block
2 alleles were amplified and sequenced directly as previ-
ously described [12]. MSP2 alleles were amplified by PCR
utilising dimorphic family specific oligonucleotides [13].
This approach identified specimens with multiple poly-
morphic alleles.
Recombinant proteins
MSP119 (Wellcome strain) was expressed as previously
[14]. MSP2 proteins representing; i) the full-length dimor-
phic family allele (MSP2/3D7 and MSP2/FC27), ii) full
length with central repeat region deleted, ie dimorphic
family specific non-repetitive region (MSP2/3D7 non-
repetitive and MSP2/FC27 non-repetitive) and iii) con-
served region alone (MSP2 CR) were expressed as
described previously [15]. Full length MSP4 [6], MSP5 [7]
and MSP6/MSP7 [9] were all expressed as previously.
RAMA-E, the C-terminal erythrocyte-binding domain of
RAMA was expressed as previously [10]. All proteins were
expressed as GST-fusions, except for MSP4 and MSP6
which were expressed with a C-terminal hexahistidine tag.
The conformational fidelity of a number of these proteins
cans be confirmed. Reduction and alkylation of the
MSP119 recombinant protein has been shown to abolish
its reactivity with several inhibitory monoclonal antibod-
ies [14], as well as reduce its recognition by human
immune sera [16]. Similar data are available for MSP4 and
MSP 5 (Lina Wang, personal communication).Malaria Journal 2007, 6:86 http://www.malariajournal.com/content/6/1/86
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Antibody measurements
The reactivity of human sera with recombinant proteins
and detection of the Ig isotypes of the antigen-specific
antibodies, using an isotype-specific method, were exam-
ined by ELISA as previously described [17]. Serum sam-
ples were diluted 1:500. Positive sera were defined as
those that give an absorbance, measured as an optical
density (OD) value, greater than the mean plus two stand-
ard deviations of absorbance obtained with sera taken
from 30 Australian blood donors with no history of expo-
sure to malaria. Positive control sera consisted of pooled
samples from 20 hyperimmune, PNG adults. By coating
microtitre plates with reference serum and incubating
with the human isotype-specific monoclonal antibodies,
the absorbances obtained were compared with the actual
values for the reference serum and used to calculate com-
pensation factors for the different isotypes, which are the
ratios of the absorbance for the given isotype to that of
IgG1. The derived compensation factors for IgG1, IgG2,
IgG3, and IgG4 were 1, 0.37, 1.07, and 1.71 respectively,
and they were used to adjust the ELISA values. Immu-
noglobulin isotypes were determined on the 20 PNG sam-
ples individually to allow comparison with the returned
traveller samples.
ELISA with MSP1 block 2 biotinylated peptides
A set of 82 overlapping 15-mer peptides encompassing all
the sequences of the allelic forms of the MSP1 block 2 [1],
was synthesized by Chiron Mimotopes Pty. Ltd. (Clayton,
Victoria, Australia). The sequences of the peptides are
described in a previous study [18]. ELISA with bioti-
nylated peptides was performed as previously described
[18]. Each plasma sample was tested in duplicate. The
wells that gave a signal two times greater than the OD
value of the wells without peptide were considered posi-
tive.
Growth inhibition mediated by MSP119 antibodies
Growth inhibition assays comparing P. falciparum (D10
strain) and transfected P. falciparum expressing the 19 kDa
C-terminal fragment of MSP1 from P. chabaudi were per-
formed as previously described [2] to determine the effect
of antibodies specific for MSP119 on parasite growth. In
brief, mature stages from synchronized parasite cultures
were incubated with patient and control, pooled non-
immune human serum diluted to 1:10, for 26 hours to
allow for schizont rupture and merozoite invasion. Inva-
sion inhibition for each parasite line was assessed micro-
scopically by comparing parasitaemia observed in the
presence of test and non-immune serum.
Statistical analysis
The frequency of positive antibody responses was com-
pared using the Chi-squared test. Comparisons between
non-parametric variables such as median ODs and immu-
noglobulin isotype ODs were performed using the Mann-
Whitney test. Correlations between independent variables
were performed using Pearson's coefficient. Invasion inhi-
bition due to MSP119antibodies was determined by com-
paring mean invasion rates for the two parasite lines using
a two-sample Student's t test. All statistical analyses were
carried out in Minitab® Release 14.
Results
Patients
Twenty patients participated in the study. There were ten
male and ten female patients. The median age was 34
years. Twelve patients acquired P. falciparum in the West-
ern Pacific region (PNG or the Solomon Islands), six in
Africa and two in Asia. There were no mixed infections.
The median parasitaemia was 24,900/µL (740-326,000/
µL). Fourteen of the patients had not had P. falciparum
previously. These patients were returning travellers from
malaria endemic areas. One other returned traveller had
two earlier episodes of P. falciparum in the six months
before the study episode. Five patients were born in
malaria endemic areas and had a past history of malaria
occurring between approximately 20 years and 3 months
before this study. These six patients had one or two previ-
ous episodes of malaria.
Fifty-five samples were collected from the 20 returned
travellers. At around the time of diagnosis (0–2 weeks) 21
samples were collected. At approximately one month post
diagnosis (4–8 weeks) 11 samples were collected and at
up to six months post diagnosis (10–41 weeks) 23 sam-
ples were collected. Multiple samples were available from
some travellers at some of these time points.
Frequency of positive antibody responses (Table 1 and 2)
Antibody responses in patient sera were measured against
the seven asexual stage antigens (MSP1, MSP2, MSP4,
MSP5, MSP6/7, and RAMA-E). Positive antibody
responses as defined above were counted in any of the
samples from a study patient. The highest frequency of
positive antibody responses to the blood stage antigens
Table 1: Rates of positive antibody responses measured by ELISA 
to merozoite surface proteins
Proportion +ve serology
MSP119 19/20
FC27 non-repetitive 18/20
FC27/3D7 non-repetitive 17/20
3D7 16/20
MSP2 conserved region/MSP6/RAMA-E 15/20
MSP4/MSP5 14/20a
MSP7 13/20a
MSP1 block 2 4/20b
a proportion +ves < MSP119, p < 0.05
b proportion +ves < MSP119, p < 0.0001Malaria Journal 2007, 6:86 http://www.malariajournal.com/content/6/1/86
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tested was to MSP119 (19/20). Importantly, 15/20
patients had antibodies to the conserved region of MSP2.
A significantly lower frequency of positive antibody
responses compared with MSP119 antibodies were seen
for MSP4/MSP5 (14/20), MSP7 (13/20) and MSP1 block
2 antibodies (4/20) (Table 1). Median antibody levels
from P. falciparum cases were significantly higher than
median negative control antibodies for all antigens tested
(Table 2).
Time course of antibodies, influence of past infection and 
parasitaemia (Table 2)
Median absorbances were significantly greater than nega-
tive control results at the first time point at around 0–2
weeks after infection. The general trend in absorbances
was for levels to be unchanged at 4–8 weeks and to
decline significantly after 10 weeks. At the last time point
measured, the median absorbances for all antigens tested
remained higher than negative controls. Samples were
grouped according to whether patients had a history of
previous malaria or not. Median absorbances were signif-
icantly higher in patients with past malaria infection only
for anti-MSP119 and anti-MSP5 responses. Otherwise, for
all other antigens tested, the median absorbances did not
differ according to whether patients had a previous history
of malaria or not. Peripheral blood parasite counts
appeared to have little impact on the antibody response
for most antigens tested. The only antibody response
where there was a significant difference in the median
ODs between patients in the upper (67,000/µL) and
lower (14,484/µL) parasitaemia quartiles was against
MSP2/FC27 non-repetitive regions. There was no signifi-
cant correlation between parasite counts and antibody
levels for any antigen.
MSP2 antibody responses (Table 3)
Responses to recombinant MSP2 antigens containing var-
ious family specific and conserved regions of the molecule
in the first patient sample collected were correlated to
assess for cross-reactive specificities. Patient samples from
P. falciparum infections containing multiple MSP2 family
alleles were identified by the MSP2 dimorphic family spe-
cific PCR. Three patient samples had multiple 3D7 and
FC27 family alleles, 11 had single 3D7 alleles and four
had single FC27 alleles. In two samples, MSP2 alleles
could not be determined. Cross-allelic family reactive
antibodies were found in this study, as there were signifi-
cant correlations between the responses to 3D7 and FC27
recombinant antigens. Firstly, correlations of responses in
all patients, malaria-naïve or previously exposed, were
analysed. (Table 3a) Significant correlations were found
in the entire sample set (ie. single 3D7 or FC27 infections,
multiple 3D7/FC27 allelic and untypeable infections) but
were also present when sera from patients shown to have
single infections with 3D7 alleles alone were analysed.
Significant correlations were present between antibodies
to the conserved region of MSP2 and the dimorphic fam-
ily specific non-repetitive MSP2 allelic and, to a lesser
extent, full length MSP2 family constructs. The correlation
between MSP2 conserved region and dimorphic family
specific non-repetitive MSP2 allelic family constructs was
most pronounced when the sera from 3D7 infections
alone were analysed. When the samples from malaria-
naïve patients alone were analysed (Table 3b), cross-
allelic family reactions were also present, but to a lesser
extent. These are shown by the significant correlations
present between the FC27 non-repetitive construct and
the conserved region in 3D7 allelic family infected indi-
viduals and between 3D7 recombinant antigens in FC27
allelic family infected individuals.
Table 2: Antibody responses compared with negative control sera and in relation to time since infection, past infection and 
parasitaemia
Median optical density MSP119 MSP2 3D7 MSP2 FC27 MSP2 3D7 
non-
repetitive
MSP2 FC27 
non-
repetitive
MSP2 
conserved 
region
MSP4 MSP5 MSP6B MSP7B RAMA-E
Overall (n = 55) 1.273a 0.296a 0.285a 0.939a 0.456a 0.291a 0.578a 0.35a 0.099a 0.295a 0.091a
0–2 weeks (n = 21) 2.95a 0.421a 0.681a 1.095a 0.635a 0.362ac 0.885a 0.407a 0.141ac 0.582a 0.089a
4–8 weeks (n = 11) 1.65ad 0.538a 0.511a 1.841ad 0.597ad 0.344ad 0.694a 0.412ad 0.154ad 0.295a 0.192ad
10–41 weeks (n = 23) 0.46a 0.137a 0.151a 0.497a 0.23a 0.146a 0.415a 0.292a 0.047a 0.25a 0.057a
No past infection (n = 37) 0.681ae 0.157a 0.229a 0.849a 0.413a 0.32a 0.61a 0.24af 0.068a 0.284a 0.089a
Past infection (n = 18) 2.82a 0.975a 0.748a 1.098a 0.598a 0.274a 0.463a 0.402a 0.121a 0.404a 0.114a
Lower quartile parasitaemia (n = 14) 0.252a 0.101a 0.08b 0.656a 0.18bg 0.221b 0.419b 0.335b 0.043b 0.285b 0.075b
Upper quartile parasitaemia (n = 14) 0.83a 0.157a 0.428a 0.684a 0.645a 0.525a 0.708b 0.198b 0.069a 0.176a 0.071a
Negative control (n = 30) -.004 0.009 0.015 0.061 0.044 0.069 0.086 0.074 0.010 0.055 0.013
a differs from neg controls p < 0.0001
b differs from neg controls p < 0.05
c Timepoint 1 vs timepoint 3 median difference p < 0.05
d Timepoint 2 vs timepoint 3 median difference p < 0.05
e No past infection vs past infection median difference p < 0.05
f No past infection vs past infection median difference p < 0.01
g Lower vs upper quartile parasitaemia median difference p < 0.05Malaria Journal 2007, 6:86 http://www.malariajournal.com/content/6/1/86
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Immunoglobulin isotypes (Table 4)
The isotypes of anti-merozoite surface protein antibodies
were compared among sera from study subjects and sera
from long-term residents of PNG who had experienced
multiple malaria infections. Significantly lower median
titres were seen in IgG2 responses to the MSP2 FC27 allele
and MSP4 in study patients compared to PNG residents.
Similarly, IgG3 responses to the MSP2 3D7 and FC27
allelic families and MSP7 were lower than in PNG con-
trols. Correlations between IgG1 and IgG3 responses were
compared in study and PNG control sera. In study and
control sera, there was a strong IgG1 predominance for
MSP119. The expected bias to IgG3 for anti-MSP2 and
anti-MSP4 responses was not present in the study sera, but
instead there was IgG1 predominance, although less
marked than for MSP119. Comparison of IgM responses in
study patients who were naïve and those who had a previ-
ous history of malaria showed no significant differences
for all antibodies tested.
Table 4: Comparison of median optical densities of immunoglobulin isotypes between study samples and PNG, positive control sera.
MSP119 MSP2 3D7 MSP2 FC27 MSP4 MSP7B
IgG1 NSa NS NS NS 0.016 : 0.044b
IgG2 NS NS 0.005 : 0.024b 0.038 : 0.017c NS
IgG3 NS 0.009 : 0.09b 0.003 : 0.35b NS 0.001 : 0.155c
IgG4 NS NS NS NS -0.002 : 0.006c
I g M N SN SN SN SN S
a not significantly different
b p < 0.05
c p < 0.001
Table 3: Correlation of antibody responses to MSP2 recombinant antigens expressing allelic family specific and conserved regions; a, 
antibodies in all patients b, antibodies in naïve patients
Pearson's correlation coefficients (r)
3D7 non-repetitive FC27 FC27 non-repetitive MSP2 conserved region
All infections (n = 20, 2 non-typeable)
3D7 0.96a 0.51b 0.42 0.55b
3D7 non-repetitive 0.48b 0.4 0.67a
FC27 0.85a 0.13
FC27 non-repetitive 0.27
All single allelic family infections (n = 15)
3D7 0.94a 0.55b 0.18 0.33
3D7 non-repetitive 0.48 0.17 0.51
FC27 0.83a 0.13
FC27 non-non-repetitive 0.17
Single 3D7 infections (n = 11)
3D7 0.95a 0.89a 0.78b 0.6
3D7 non-repetitive 0.82b 0.85a 0.72b
FC27 0.57 0.43
FC27 non-repetitive 0.92a
Single FC27 infections (n = 4)
3D7 0.96b 0.33 -0.14 -0.35
3D7 non-repetitive 0.39 -0.12 -0.24
FC27 0.87 -0.81
FC27 non-repetitive -0.78
Multiple 3D7/FC27 infections (n = 3)
3D7 0.98 0.79 0.89 0.63
3D7 non-repetitive 0.67 0.79 0.76
FC27 0.98 0.03
FC27 non-repetitive 0.21
a p < 0.001
b p < 0.05Malaria Journal 2007, 6:86 http://www.malariajournal.com/content/6/1/86
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MSP1 Block 2 antibody responses
Antibodies to the MSP1 block 2 epitopes were found in a
minority of patients (4/20). In these patients, antibodies
were found to be restricted to one allelic family type in
three of the four patients and were also restricted to a max-
imum of four epitopes. The same temporal pattern as with
the other antigens was found with relatively high absorb-
ances at the time of infection followed by a reduction over
the next six months. In one patient, antibodies to a single
K1 and RO33 family allele could be detected. This individ-
ual had no past history of malaria infection. Genotyping
of the MSP1 block 2 PCR showed the presence of a single
K1 dimorphic family allele in this individual.
Growth inhibition due to MSP119 antibodies
Significant invasion inhibiting anti-MSP119  antibodies
were detected in a total of nine patient samples. In these
samples, there was a 14.8 – 48.7% reduction of red blood
cell invasion when P. falciparum was compared with the P.
falciparum MSP119 – P. chabaudi transfectant. The antibod-
ies were short-lived, being present soon after the patent
infection (median 36 days; range 9–249 days) and declin-
ing in 5/9 cases (tested negative at median 185 days post
infection; range 170 – 236 days.). In three cases, the inva-
sion inhibiting antibodies were detected using the stand-
ard assay conditions and serum dilution of 1:10.
However, nine serum samples caused inhibition of sch-
izont rupture, which interfered with assessment of growth
inhibition at the standard dilution. When these sera were
diluted to 1:90, six were found to contain invasion inhib-
iting anti-MSP119 antibodies invasion. There was no dif-
ference in frequency of these functional MSP119
antibodies according to whether patients had a past his-
tory of malaria or not (p = 0.2, 2-tailed Fisher's exact) but
anti-MSP119 absorbances were significantly higher in the
group with invasion inhibiting antibodies (2.31 vs. 0.49 p
< 0.05).
Discussion
Antibody responses to malaria in people living in
endemic regions are complex and represent the summa-
tion of multiple infections, typically beginning in infancy.
Repeated infections are required to stimulate the non-ster-
ile immunity found in adults living in malaria hyperen-
demic areas. Little is known about the immune responses
to a single P. falciparum infection. In the group of previ-
ously healthy, mostly P. falciparum naïve, adults studied
here, antibodies were measured to seven different malaria
proteins including multiple MSP1 and MSP2 regions and
alleles. Relatively short-lived antibody responses were
found most commonly with MSP4/5/7 and MSP1 block 2
antibodies being significantly less frequent than the rest of
the antibodies tested. In nine subjects, functional, inva-
sion inhibiting MSP119  antibodies were shown to be
Table 3b: Naïve patients
Pearson's correlation coefficients (r)
3D7 non-repetitive FC27 FC27 non-repetitive MSP2 conserved region
All infections (n = 14, 2 non-typeable)
3D7 0.94a 0.25 0.24 0.5
3D7 non-repetitive 0.21 0.24 0.64b
FC27 0.92a -0.17
FC27 non-repetitive 0.21
All single allelic family infections (n = 10)
3D7 0.85b 0.45 0.17 -0.12
3D7 non-repetitive 0.31 0.11 0.12
FC27 0.93a -0.11
FC27 non-non-repetitive 0.03
Single 3D7 infections (n = 6)
3D7 0.81 0.74 0.36 0.03
3D7 non-repetitive 0.45 0.63 0.46
FC27 0.32 0.09
FC27 non-repetitive 0.89b
Single FC27 infections (n = 4)
3D7 0.96b 0.33 -0.14 -0.35
3D7 non-repetitive 0.39 -0.12 -0.24
FC27 0.87 -0.81
FC27 non-repetitive -0.78
a p < 0.001
b p < 0.05Malaria Journal 2007, 6:86 http://www.malariajournal.com/content/6/1/86
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present. Importantly, frequent antibody reactions to con-
served regions of MSP2 have been documented for the
first time in humans exposed to a single P. falciparum
infection. Similarly, the MSP2 isotype response was not
skewed towards IgG3 antibodies as previously shown
[19]. These features of the immune response to P. falci-
parum seen in naïve adults contrast markedly with the
MSP2 repeat region dominated response found in malaria
endemic populations [19].
MSP119 appeared to be particularly immunogenic in this
population as shown by the presence of invasion inhibit-
ing antibodies in 9/20 patients that were present one
month after infection but mostly disappeared by six
months. Of interest, a significant proportion (45%) of
sera inhibited schizont rupture in growth assays, a prop-
erty much more rarely encountered in sera from endemic
areas (data not shown). Dilution of these sera revealed an
underlying capacity to inhibit merozoite invasion. Func-
tional MSP119 antibodies, as detected by this method,
were correlated with protection from P. falciparum infec-
tion in Kenyan children and adults while MSP119 antibod-
ies measured by ELISA were not [20]. Other studies do not
show the same level of correlation and the exact protective
importance of this antibody subpopulation is not yet
defined in all populations [21,22]. Nevertheless, it seems
reasonable to suggest that the presence of such antibodies
indicates a capacity of convalescent sera to exert a level of
anti-parasitic action after a single infection. It will be par-
ticularly interesting to discover whether similar levels of
inhibitory antibodies are induced in children resident in
endemic areas, after their first bout of malaria. This may
represent a previously unrecognized mechanism for short-
term host protection.
MSP1 block 2, by contrast, was much less antigenic. Only
4/20 of the adult population were positive for any MSP1
block 2 antibodies. This contrasts with previous field stud-
ies that also measured MSP1 block 2 antibodies to allelic
family specific, short peptides. An age-dependant increase
in antibodies to 58.3% of 10–15 year old Ghanaian chil-
dren was found [23]. The low frequency of antibodies
MSP1 block 2 in this study does not appear to be due to
failure to detect short-lived antibodies [24] as the patients
were assayed immediately after their clinical episode of
malaria with fine epitope mapping using 15 mer peptides
that cover the MSP1 block 2 locus with significant redun-
dancy. The epitopes recognized in this study were all from
relatively constant regions of the MSP1 block 2 alleles.
One patient who had no past history of malaria infection
had antibodies detected to both K1 and RO33 allelic fam-
ily antigens despite being infected with only a K1 family
isolate. The observed low antigenicity of MSP1 block 2 in
adults mostly after their first P. falciparum infection sug-
gests that the potentially protective antibodies to this
region [23] reflect a high frequency of previous episodes
of malaria. The other antigens assayed with relatively low
levels of seroreactivity were MSP4/5 and MSP7, which,
like MSP1 block 2, appear to have higher rates of seropos-
itivity in malaria endemic populations [9,17].
For the first time, in this study, there is evidence of com-
monly occurring antibody responses to the conserved
regions of MSP2. This contrasts with prevailing evidence
that suggests the immunodominance of the central amino
acid repeat region following repeated infections of
humans [19] or immunization studies [25]. Antibody
responses to the conserved regions of MSP2 were docu-
mented in 15/20 of study patients. By contrast, antibodies
from pooled PNG adult serum to this region were below
the cut-off level so this result is highly significant. When
the same methodology was used to study semi-immune
Vietnamese teenagers and adults, only 1/15 had antibod-
ies to the MSP2 conserved region [15]. No measurable
antibodies to the conserved regions of MSP2 were
induced by vaccination with the 3D7 allele in five to nine
year old children in the Combination B trial [25]. A
minority of non-immune Swiss travellers have been
shown to have antibodies to the conserved regions of
MSP2 by non-quantitative immunoblot [26].
Additionally, significant correlations between MSP2
allelic family constructs have been shown. More signifi-
cant correlations between antibodies were found in indi-
viduals with a past history of one to two episodes of
malaria. Even in previously naïve individuals, apparently
cross-allelic family reactive antibodies were present. It
appears that these are attributable to antibodies to the
conserved region of MSP2. The correlations we have cal-
culated are based on small numbers of samples. Previous
studies of anti-MSP2 immune responses in populations
living in hyperendemic areas have shown that antibodies
are dimorphic family specific [19], but that there is exten-
sive intra-dimorphic family immune response cross-reac-
tivity [27]. Vaccine-derived MSP2 antibodies were
restricted to the 3D7 specific regions of the vaccine anti-
gen [25]. Limited inter-dimorphic family antibody cross
reactivity has been recognized previously for MSP2 after
patent malaria in two non-immune patients [26] and in
this study, inter allelic family specific antibodies to MSP1
block 2 were found in one patient.
Protective antibodies to repeat regions of MSP2 have been
shown to change from IgG1 to IgG3 dominated responses
with aging indicating a maturation of the immune
response [28,29]. The patients studied here do not show
this same isotype pattern and MSP2 antibodies were pre-
dominantly IgG1. Thus, these non-immune adults stud-
ied herein have MSP2 responses that differ in target and
isotype from hyperimmune sera. It may be that the repeatMalaria Journal 2007, 6:86 http://www.malariajournal.com/content/6/1/86
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region dominated MSP2 responses seen in malaria
endemic regions result from the repeated infections expe-
rienced by infants with immature immune systems that
do not recognise the conserved regions of MSP2. Simi-
larly, the IgG3 dominated anti-MSP7 response in immune
adults [9] was not seen in this study population. Previ-
ously naïve patients were also not found to have higher
IgM responses to any of the antigens tested than adults
with a past history of malaria.
Antibody responses trended to declining levels over the 6
months of follow up. At the final bleed though, antibod-
ies to all antigens tested remained positive. The level of
parasitaemia, not unexpectedly, had essentially no influ-
ence on the level of antibodies measured. In field settings
with seasonal malaria transmission, MSP119 and MSP1
block 2 antibodies have been shown to decrease over dry
seasons [24]. Antibodies to chondroitin sulphate A-bind-
ing variant surface antigens have also been shown to be
short-lived in women with pregnancy associated malaria
but their presence correlates with protection against infec-
tion of the placenta [30]. Temporary humoral immune
responses seem to be common for malaria antigens.
Conclusion
Viewed together, the antibody responses measured to
MSP1 block 2 and MSP2 suggest that singly infected
adults have a very different immune response in compar-
ison with those living in malaria-endemic areas. It appears
that antibodies to MSP1 block 2 become much more com-
mon with repeated infection while those to MSP2 become
dominated by allelic family specificities particularly to the
central amino acid repeat region with extinction of
responses to the conserved region. The development of
cross allelic-family reactive MSP2 antibodies after a single
native infection with P. falciparum has been documented.
These data strongly support the use of MSP2 for malaria
vaccination. These data are also supportive of MSP119 vac-
cine development given it was highly immunogenic after
single infection with functional antibodies measured. As
functional MSP119 antibodies have been shown to be cor-
related with protection [20] it now appears to be impera-
tive to develop assays to test for functional antibodies in
future vaccine trials of other antigens, such as MSP2.
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